Khanna, D;
Tashkin, DP;
Denton, CP;
Lubell, MW;
Vazquez-Mateo, C;
Wax, S;
(2018)
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.
Rheumatology
10.1093/rheumatology/key151.
(In press).
Preview |
Text
Denton_Ongoing_clinical_trials_VoR.pdf - Published Version Download (423kB) | Preview |
Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.
| Type: | Article |
|---|---|
| Title: | Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/rheumatology/key151 |
| Publisher version: | https://doi.org/10.1093/rheumatology/key151 |
| Language: | English |
| Additional information: | Copyright © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Keywords: | Systemic sclerosis; pulmonary fibrosis; interstitial lung disease; study design; abituzumab; bortezomib; dabigatran, nintedanib, pirfenidone |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10050630 |
Archive Staff Only
 |
View Item |
